MTF annually assesses drug use among the Nation's 8th, 10th, and 12th grade students. Steroid use among all three grades assessed remained unchanged from 2005 to 2006, for both boys and girls, although significant reductions were noted since 2001 for lifetime** use. Past year use was reported by percent of 8th-graders, percent of 10th-graders, and percent of 12th-graders in 2006. Perceived risk of steroid use, which is collected only for seniors, increased significantly, from percent in 2005 to percent in 2006. Disapproval of steroid use, also collected only for seniors, did not change significantly from 2005 to 2006.
Adderall is the most commonly prescribed stimulant for treating symptoms of ADHD. People who habitually use Adderall to increase their productivity and improve their mental focus have the highest risk of becoming addicted.
Many more abuse-deterrent formulations are entering the market. In November 2014 the FDA approved Hysingla ER (hydrocodone bitartrate), an acetaminophen-free, extended-release (ER) opioid for severe pain requiring daily, long-term treatment and for which no alternatives exist. As with other abuse-deterrent forms, Hysingla ER abuse-deterrent properties may reduce, but not totally prevent, abuse of the drug. The tablet forms a thick gel and cannot be easily prepared for injection, and is difficult to crush, break or dissolve. The most common side effects of Hysingla ER are constipation, nausea, fatigue, and dizziness. Targiniq ER (oxycodone/naloxone), Oxycontin (oxycodone [reformulated]), Embeda (morphine/naltrexone), Zohydro ER (hydrocodone), Troxyca ER (naltrexone/oxycodone), Arymo ER (morphine sulfate extended-release tablet), and Vantrela ER (hydrocodone bitartrate) are other long-acting but abuse-deterrent pain medications.